Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Merck KGaA Add to portfolio

DAXX:MRK, Sep 26, 09:40 UTC

Latest DAXX:MRK News

Filter your feed

Apply Filter

Friday, September 21


News

Why Merck Stock Has Risen 28.2% Year-to-Date

MRK

Merck (MRK) stock has risen from $54.93 on January 2 to $70.42 on September 18—a 28.2% increase year-to-date. The performance of Merck stock has been closely related to the sales, clinical trial outcomes, and regulatory decisions for the company’s leading immuno-oncology drug, Keytruda. Approved in 13 indications and eight tumor types, Keytruda reported sales of $1.7 billion in the second quarter.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

XOMA Acquires Royalty Interest Position from Agenus on Seven Assets Being Developed by Merck and Incyte Nasdaq:XOMA

MRK INCY

EMERYVILLE, Calif., Sept. 21, 2018 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today that for $15.0 million, it has acquired from Agenus (NASDAQ: AGEN) a partial interest position in the rights to potential milestone and royalty payments associated with seven immuno-oncology antibodies currently being developed by Merck and Incyte under their collaborations with Agenus. “These assets possess all the characteristics we have established for our business model: outstanding development partners, mid-stage to early stage assets, important therapeutic categories, and sizable royalty commitments. The Company’s royalty-aggregator business model includes acquiring additional licenses to partner-funded programs. For more information, visit www.xoma.com. Forward-Looking StatementsCertain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the potential of XOMA’s portfolio of partnered programs and licensed technologies to generate royalty proceeds over time and create potential cash flow, including from potential milestone and royalty payments associated with immuno-oncology programs of Agenus. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that we may not receive any significant royalty or milestone payments from Agenus’ assets, our product candidates subject to out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; we may not be successful in entering into out-license agreements for our product candidates; if our therapeutic product candidates do not receive regulatory approval, our third-party licensees will not be able to manufacture and market them.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Thursday, September 20


News

Merck Publishes Corporate Responsibility Report

MRK

Report Illustrates How Merck Creates Sustainable Value for Business and Society. "Our company has an important role to play in tackling some of humanity's greatest challenges," said Kenneth C. Frazier, chairman and chief executive officer, Merck. "By fostering a long-term, strategic approach to our business and our contributions to society, we can not only strengthen our future as a company but also fulfill our commitments to make this a better, healthier world for all." Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

How Accenture’s Partnership with Merck Could Be Helpful

MRK

Accenture (ACN) has teamed up with Merck & Co. (MRK), one of the leading pharmaceutical giants outside the United States, to drive production, effectiveness, and innovation in the initial stages of drug development. Both companies have included Amazon’s (AMZN) AWS (Amazon Web Services) cloud computing, The involvement of the leading public cloud service provider should allow MSD to introduce a cloud-based informatics research platform to support the life sciences industry related to drug manufacturing.

Read Full Details

Topics:
  • Business
  • Health
  • Science

Wednesday, September 19


News

Osteosarcoma - Pipeline Review (H2 2018) Featuring Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Merck, Pfizer, and more - ResearchAndMarkets.com

BAYN MRK +3 more BAYN MRK AMGN BMY PFE

Osteosarcoma - Pipeline Review (H2 2018) Featuring Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Merck, Pfizer, and more - ResearchAndMarkets.com. DUBLIN--(BUSINESS WIRE)--The "Osteosarcoma - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.Osteosarcoma - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Osteosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Osteosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 22, 8, 1, 23 and 5 respectively.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Science

Tuesday, September 18


News

Accenture, Merck Amazon AWS Partner for Cloud Platform - September 18, 2018

MRK ACN

Accenture plc ACN, Merck MRK and Amazon’s AMZN Amazon Web Services (“AWS”) have collaborated to develop a cloud-based informatics research platform. Built on AWS, this platform is one of the solutions that Accenture Applied Life Sciences Solutions practice offers. The platform can be availed by a range of life sciences industry players such as pharmaceutical, biotech and scientific research organizations to enhance productivity, efficiency and innovation in the early stages of drug development. Brad Michel, managing director of Accenture Scientific Informatics Services, stated that “understanding the industry’s need to drive faster, more efficient and more innovative scientific research, we are pleased to collaborate with Merck and AWS to launch the platform and associated ecosystem to help our clients accelerate the discovery of new, targeted treatments for patients.”.

Read Full Details

Topics:
  • Business
  • Science
News

IMV Inc. Announces Early Positive Results from Phase 2 Clinical Trial of Lead Candidate DPX-Survivac in Combination with Merck’s Keytruda® in Patients with DLBCL

MRK

DARTMOUTH, Nova Scotia, Sept. 18, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced details of the initial data from an ongoing investigator-sponsored Phase 2 clinical trial. The preliminary data included assessment of safety and clinical activity (based on modified Cheson criteriai) for the first four evaluable patients who have completed their first CT scan after the start of treatment. “These data have provided IMV’s first clinical data for DPX-Survivac in combination with Merck’s Keytruda, and we are encouraged by these early signs of clinical activity in DLBCL,” said Frederic Ors, IMV’s Chief Executive Officer. One of IMV’s key objectives is to provide patients with more effective treatment options by expanding our clinical program to include other hard-to-treat cancer indications. While these data are preliminary, we are pleased to see the promising initial activity in a blood cancer, where checkpoints inhibitors alone have thus far shown modest anti-cancer activity.” ii.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Financial

Monday, September 17


News

Lenvima Could Significantly Boost Merck’s Revenue Growth

MRK

In August, the FDA approved Merck’s (MRK) and Eisai’s Lenvima in the first-line setting for the treatment of individuals with unresectable hepatocellular carcinoma (or HCC). The FDA’s approval of Lenvima in the first-line setting for the treatment of HCC was based on data from the REFLECT trial.

Read Full Details

Topics:
  • Business
  • Health
  • Entertainment
News

Accenture and Merck Collaborate with Amazon Web Services to Launch a Research Platform to Drive Innovation in Drug Discovery and Scientific Research

MRK ACN

The new research platform, being developed by Merck and Accenture, will enable an ecosystem that accelerates innovation by creating open, industry-standard application programming interfaces for core research functions, allowing researchers to rapidly adopt new capabilities. Scientific application providers, content providers and technology innovators will benefit from lower barriers to entry as they bring new capabilities to market, helping life sciences companies re-imagine processes, user experiences, and approaches to data-intensive research. Incorporating a modern user interface and a secure, multi-tenant environment, the platform will unify user experience elements and enable easier collaboration across the research and development (R&D) enterprise, including with external partners. “Pharmaceutical companies are seeking ways to adopt a cloud-first strategy to enhance and advance their R&D drug discovery practices, and we’re thrilled to be at the leading edge of these efforts as we work with Accenture to launch a new industry platform,” said Mike Clayville, vice president, Worldwide Commercial Sales and Business Development, Amazon Web Services, Inc.

Read Full Details

Topics:
  • Business
  • Technology
  • Financial
  • Science

Friday, September 14


News

Friday’s Vital Data: Apple, Advanced Micro Devices and Merck

MRK AAPL

On the CBOE, the single-session equity put/call volume ratio dropped to a three-month low of 0.50 amid a swell in call activity. As a result, the 10-day moving average ticked lower to 0.61. Finally, Merck (NYSE:MRK) saw options volume spike ahead of its ex-dividend date. Calls claimed an above average 64% of the day’s take. However, this could once again be short-term profit taking activity from AAPL options traders. For instance, the October put/call open interest ratio comes in at 1.27. Helping to boost AMD in the early going was an initiation from FBN Securities, which started the stock at “outperform” with a $40 price target. However, valuation concerns got the better of AMD stock.

Read Full Details

Topics:
  • Business
  • Financial